|Mr. David C. Paul||Co-Founder & Exec. Chairman||887.71k||11.43M||1967|
|Mr. David M. Demski||CEO, Pres & Director||1.36M||6.85M||1958|
|Mr. Daniel T. Scavilla||Exec. VP & Chief Commercial Officer||792.42k||2.45M||1965|
|Mr. Keith W. Pfeil||Sr. VP & CFO||N/A||N/A||1980|
|Mr. Brian J. Kearns||Sr. VP of Bus. Devel. & Investor Relations||N/A||N/A||1967|
Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its spine product portfolio includes a range of implant and surgical approach options that could be used to treat degenerative, deformity, tumor, and trauma conditions affecting the spine from the occiput to the sacrum. The company also offers imaging, navigation, and robotic assisted surgery technology solutions, as well as motion preservation technologies, such as dynamic stabilization, total disc replacement and interspinous distraction devices, and interventional pain management solutions to treat vertebral compression fractures. In addition, it provides regenerative biologic products, such as allografts and synthetic alternatives that are adjunctive treatments used in combination with stabilizing implant hardware. Further, the company offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems. Additionally, it distributes human cell, tissue, and cellular and tissue based products. The company sells its implants and related disposables primarily to hospitals through direct sales representatives and independent distributors in the United States and internationally. Globus Medical, Inc. was founded in 2003 and is headquartered in Audubon, Pennsylvania.
Globus Medical, Inc.’s ISS Governance QualityScore as of July 29, 2019 is 10. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 10; Compensation: 8.